skip to primary navigationskip to content

07.12.16 Gurdon Institute secures further five years of funding as a Wellcome Centre

last modified Dec 07, 2016 07:06 AM
Wellcome announce the renewal of the Gurdon Institute's core funding along with that of neighbouring Stem Cell Institute
07.12.16 Gurdon Institute secures further five years of funding as a Wellcome Centre

The Wellcome/ Cancer Research UK Gurdon Institute, University of Cambridge

Cambridge’s Gurdon Institute and Stem Cell Institute receive five year funding boost

Two Cambridge institutes have today been confirmed as major research centres by biomedical research charity Wellcome, receiving continued support for a further five years.  The centres will be co-funded by Cancer Research UK (CRUK) and the Medical Research Council (MRC) respectively.

The Wellcome/MRC Cambridge Stem Cell Institute and Wellcome/CRUK Gurdon Institute have been named as two of 14 Wellcome Centres announced today, all of which aim to advance our understanding of health and disease, and span fundamental and social sciences, clinical research and engineering.

At Wellcome Centres groups of world-class researchers with a joint vision come together to share facilities, collaborate, and benefit from the dynamic research, cultural and training environment.  This special environment allows them to deliver world-leading research and high-impact translation.  

The Gurdon Institute is a world-leading centre for research at the interface between developmental biology and cancer biology, using several model systems, from yeast to human organoids. Across the Institute’s 25-year history this research has led to major insights into the molecular and cellular defects that give rise to cancer and other diseases of ageing, and several findings have been successfully translated into drug discovery through spinout companies.

Professor Daniel St Johnston, Director, Wellcome/CRUK Gurdon Institute, says: "We are delighted that the Wellcome Trust and Cancer Research UK have decided to renew the Centre funding for the Gurdon Institute, which will allow us to continue our ground-breaking research on the links between developmental biology and cancer."

The Stem Cell Institute was established in 2012 and is a world-leading centre for stem cell research. Stem cells give rise to the multitude of cell types that make up our bodies, and their dysfunction underlies numerous diseases including many current global health challenges. Stem cells also provide unique tools for modelling disease and for generating novel cell-based therapies. In 2018, its researchers will come together in a new purpose-built building embedded within the Cambridge Biomedical Campus, close to multiple other research institutes and adjacent to Addenbrooke’s and Papworth hospitals.

Professor Tony Green, Director of the Wellcome/MRC Cambridge Stem Cell Institute, says: “Stem cell research offers unrivalled opportunities for developing new approaches to the management of disease, and I am delighted that both the Wellcome Trust and the Medical Research Council will continue to support our pioneering research at this exciting time.”

Wellcome’s Director, Dr Jeremy Farrar, says: “Wellcome Centres play a special role in the global research ecosystem. By creating places where researchers can flourish we can catalyse world-leading research and translation, and amplify its influence and impact.

“At Wellcome we believe in long term support for discovery-driven science, and Wellcome Centres are an outstanding environment for researchers to further our understanding of fundamental biology, accelerate translation to clinical practice, and explore the social and cultural context of medicine."

For more information about the centres visit:



Text reproduced from news story on University of Cambridge website.

Studying development to understand disease

The Gurdon Institute is funded by Wellcome and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.

combinedLogo x3 trans2018


Share this

Immune Cell Dynamics Unfolded by Single-Cell Technologies

Chromatin Accessibility Impacts Transcriptional Reprogramming in Oocytes

Integrin α2 marks a niche of trophoblast progenitor cells in first trimester human placenta

Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells by rebalancing the Transportin-1 nuclear import pathway

SLAM-ITseq: Sequencing cell type-specific transcriptomes without cell sorting

SRSF3 maintains transcriptome integrity in oocytes by regulation of alternative splicing and transposable elements

scmap: projection of single-cell RNA-seq data across data sets

Single-cell transcriptomics reveals a new dynamical function of transcription factors during embryonic hematopoiesis

Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48

The developmental origin of brain tumours: a cellular and molecular framework

Bioinformatics challenges and perspectives when studying the effect of epigenetic modifications on alternative splicing

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity

Combinational Treatment of Trichostatin A and Vitamin C Improves the Efficiency of Cloning Mice by Somatic Cell Nuclear Transfer

Predominant Asymmetrical Stem Cell Fate Outcome Limits the Rate of Niche Succession in Human Colonic Crypts

G9a regulates temporal preimplantation developmental program and lineage segregation in blastocyst

Link to full list on PubMed